

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 APR 04 STN AnaVist, Version 1, to be discontinued  
NEWS 3 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats  
NEWS 4 APR 28 EMBASE Controlled Term thesaurus enhanced  
NEWS 5 APR 28 IMSRESEARCH reloaded with enhancements  
NEWS 6 MAY 30 INPAFAMDB now available on STN for patent family searching  
NEWS 7 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option  
NEWS 8 JUN 06 EPFULL enhanced with 260,000 English abstracts  
NEWS 9 JUN 06 KOREAPAT updated with 41,000 documents  
NEWS 10 JUN 13 USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications  
NEWS 11 JUN 19 CAS REGISTRY includes selected substances from web-based collections  
NEWS 12 JUN 25 CA/CAplus and USPAT databases updated with IPC reclassification data  
NEWS 13 JUN 30 AEROSPACE enhanced with more than 1 million U.S. patent records  
NEWS 14 JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations  
NEWS 15 JUN 30 STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in  
NEWS 16 JUN 30 STN AnaVist enhanced with database content from EPFULL  
NEWS 17 JUL 28 CA/CAplus patent coverage enhanced  
NEWS 18 JUL 28 EPFULL enhanced with additional legal status information from the epoline Register  
NEWS 19 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements  
NEWS 20 JUL 28 STN Viewer performance improved  
NEWS 21 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced  
NEWS 22 AUG 13 CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998  
NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008  
NEWS 24 AUG 15 CAplus currency for Korean patents enhanced  
NEWS 25 AUG 25 CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching  
NEWS 26 AUG 27 CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 14:10:44 ON 02 SEP 2008

FILE 'REGISTRY' ENTERED AT 14:11:00 ON 02 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 SEP 2008 HIGHEST RN 1045602-82-1  
DICTIONARY FILE UPDATES: 1 SEP 2008 HIGHEST RN 1045602-82-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\Stnexp\Queries\10554202.str



```

chain nodes :
11 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17
chain bonds :
1-19 7-11 11-12 19-20 20-21 21-22
ring bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
exact/norm bonds :
1-19 7-11 11-12 19-20 21-22
exact bonds :
20-21
normalized bonds :
1-2 1-6 2-3 2-7 3-4 3-10 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15
15-16 16-17
isolated ring systems :
containing 1 : 12 :

```

```

Hydrogen count :
9:= exact 1
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 19:CLASS 20:CLASS
21:CLASS 22:CLASS


```

L1           STRUCTURE UPLOADED

```

=> d L1
L1 HAS NO ANSWERS
L1                   STR

```



Structure attributes must be viewed using STN Express query preparation.

=> s 11 full  
FULL SEARCH INITIATED 14:11:32 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1269 TO ITERATE

100.0% PROCESSED 1269 ITERATIONS 411 ANSWERS  
SEARCH TIME: 00.00.01

L2 411 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
SESSION  
FULL ESTIMATED COST ENTRY 178.36 178.57

FILE 'CAPLUS' ENTERED AT 14:11:37 ON 02 SEP 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Sep 2008 VOL 149 ISS 10  
FILE LAST UPDATED: 1 Sep 2008 (20080901/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:


<http://www.cas.org/legal/infopolicy.html>

=> s 12  
L3 9 L2

=> d 13 1- ibib abs hitstr  
YOU HAVE REQUESTED DATA FROM 9 ANSWERS - CONTINUE? Y/(N):y


L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2008:631491 CAPLUS  
DOCUMENT NUMBER: 149:44599  
TITLE: Discovery of Novel Small-Molecule Inhibitors of Human  
Epidermal Growth Factor Receptor-2: Combined Ligand  
and Target-Based Approach  
AUTHOR(S): Gundla, Rambabu; Kazemi, Roza; Sanam, Ramadevi;  
Muttineni, Ravikumar; Sarma, Jagarlapudi A. R. P.;  
Dayam, Raveendra; Neamati, Nouri  
CORPORATE SOURCE: Department of Pharmacology and Pharmaceutical  
Sciences, School of Pharmacy, University of Southern  
California, Los Angeles, CA, USA  
SOURCE: Journal of Medicinal Chemistry (2008), 51(12),  
3367-3377  
CODEN: JMCMAR; ISSN: 0022-2623  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Consensus virtual screening models were generated and validated utilizing  
a set of known human epidermal growth factor receptor-2 (HER2) inhibitors  
and modeled HER2 active and inactive state structures. The virtual  
screening models were successfully employed to discover a set of  
structurally diverse compds. with growth inhibitory activity against  
HER2-overexpressing SKBR3 breast cancer cell line. A search of a 3D  
database containing 350000 small-mols. using the consensus models retrieved  
531 potential hits. Of the 531 hits, 57 were selected for testing in  
SKBR3 cells on the basis of structural novelty and desirable drug-like  
properties. Seven compds. inhibited growth of SKBR3 cells with IC50  
values <10  $\mu$ M. These lead compds. have desirable physicochem.  
properties and are excellent candidates for further optimization.  
IT 786689-52-9 871019-02-2  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(discovery of novel small-mol. inhibitors of human EGFR-2: combined  
ligand and target-based approach)  
RN 786689-52-9 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[(1R)-2-  
(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 871019-02-2 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-2-methyl- (CA INDEX NAME)



REFERENCE COUNT:

54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:338435 CAPLUS

DOCUMENT NUMBER: 148:552721

TITLE: Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

AUTHOR(S): Barlaam, Bernard; Acton, David G.; Ballard, Peter; Bradbury, Robert H.; Cross, Darren; Ducray, Richard; Germain, Herve; Hudson, Kevin; Klinowska, Teresa; Magnien, Francoise; Ogilvie, Donald J.; Olivier, Annie; Ross, Helen S.; Smith, Robin; Trigwell, Cath B.; Vautier, Michel; Wright, Lindsay

CORPORATE SOURCE: Centre de Recherches, Z.I.S.E. La Pompelle, AstraZeneca, Reims, 51689, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2008),  
 18(6), 1799-1803  
 CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English


AB We have identified a new series of C-5 substituted indazolylaminoquinazolines as potent erbB2 kinase inhibitors. The lead compound 22 showed excellent *in vitro* potency, good phys. properties, acceptable oral pharmacokinetics in rat and dog, and low human *in vitro* clearance. It showed at least equivalent activity dose for dose compared to lapatinib in various erbB2- or EGFR-driven xenograft models after chronic oral administration.

IT 871019-56-6  
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (neutral 5-substituted 4-indazolylaminoquinazolines as oral inhibitors of erbB2 receptor TK)

RN 871019-56-6 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:85165 CAPLUS

DOCUMENT NUMBER: 148:369248

TITLE: A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase

AUTHOR(S): Barlaam, Bernard; Ballard, Peter; Bradbury, Robert H.; Ducray, Richard; Germain, Herve; Hickinson, D. Mark; Hudson, Kevin; Kettle, Jason G.; Klinowska, Teresa; Magnien, Francoise; Ogilvie, Donald J.; Olivier, Annie; Pearson, Stuart E.; Scott, James S.; Suleman, Abid; Trigwell, Cath B.; Vautier, Michel; Whittaker, Robin D.; Wood, Robin

CORPORATE SOURCE: Centre de Recherches, AstraZeneca, Reims, 51689, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2008), 18(2), 674-678

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 148:369248

AB Starting from initial lead 1 containing a basic 5-substituent, optimization of the glycolamide-derived neutral 5-substituent led to potent inhibitors of erbB2 with good pharmacokinetics. Representative compds. 19 and 21 inhibited phosphorylation of erbB2 in a mouse BT474C xenograft model after oral administration.


IT 871018-78-9P 871019-34-0P 871019-56-6P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)

RN 871018-78-9 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-34-0 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-56-6 CAPLUS

CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 871018-52-9P 871018-67-6P 871018-77-8P  
 871018-80-3P 871018-90-5P 871018-91-6P  
 871019-24-8P 871019-49-7P 871019-55-5P  
 871019-96-4P 871021-07-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)


RN 871018-52-9 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy- (CA INDEX NAME)



RN 871018-67-6 CAPLUS


CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)



RN 871018-77-8 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-80-3 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-90-5 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-91-6 CAPLUS


CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871019-24-8 CAPLUS


CN Acetamide, N-(2-hydroxyethyl)-N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-49-7 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-55-5 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-96-4 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871021-07-7 CAPLUS

CN Propanamide, N,N-dimethyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1170549 CAPLUS  
 DOCUMENT NUMBER: 147:514416  
 TITLE: Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase  
 AUTHOR(S): Ballard, Peter; Barlaam, Bernard C.; Bradbury, Robert H.; Dishington, Allan; Hennequin, Laurent F. A.; Hickinson, D. Mark; Hollingsworth, Ian M.; Kettle, Jason G.; Klinowska, Teresa; Ogilvie, Donald J.; Pearson, Stuart E.; Scott, James S.; Suleman, Abid; Whittaker, Robin; Williams, Emma J.; Wood, Robin; Wright, Lindsay  
 CORPORATE SOURCE: Cancer and Infection Research, AstraZeneca, Mereside, Macclesfield, SK10 4TG, UK  
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(22), 6326-6329  
 CODEN: BMCLE8; ISSN: 0960-894X  
 PUBLISHER: Elsevier Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 147:514416  
 GI




I

AB Neutral 5-substituted 4-anilinoquinazolines addressed high *in vivo* clearance and phospholipidosis associated with previous basic compds. A representative compound 8a (I) inhibited tumor growth in a mouse xenograft model when co-administered with the cytochrome P 450 inhibitor 1-aminobenzotriazole (ABT), and data are consistent with pharmacol. primarily reflecting inhibition of erbB2 receptor tyrosine kinase.

IT 853000-40-5P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)

RN 853000-40-5 CAPLUS

CN Acetamide, N-[2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy)ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



IT 853000-46-1P 853000-98-3P 853001-06-6P  
853001-08-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)

RN 853000-46-1 CAPPLUS

CN Acetamide, N-[(2R)-2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-98-3 CAPPLUS

CN Acetamide, N-[(2S)-2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-06-6 CAPLUS

CN Acetamide, N-[(1R)-2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.




RN 853001-08-8 CAPLUS

CN Acetamide, N-[(1S)-2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




IT 853001-89-5P 853001-92-0P 853002-14-9P  
 853002-17-2P 956409-93-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (anilinoquinazolines as inhibitors of erbB2 receptor tyrosine kinase)  
 RN 853001-89-5 CAPLUS  
 CN Phenol, 2-chloro-4-[ [5-[2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA  
 INDEX NAME)




RN 853001-92-0 CAPLUS  
 CN Phenol, 2-chloro-4-[ [5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-  
 4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853002-14-9 CAPLUS  
 CN Phenol, 2-chloro-4-[ [5-[(2R)-2-(methylamino)propoxy]-4-quinazolinyl]amino]-  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-17-2 CAPLUS

CN Phenol, 2-chloro-4-[ [5-[(2S)-2-(methylamino)propoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 956409-93-1 CAPLUS

CN Phenol, 2-chloro-4-[ [5-[(1S)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:



17

THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:619371 CAPLUS  
 DOCUMENT NUMBER: 147:72781  
 TITLE: 4-Anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors and their preparation, pharmaceutical compositions, and use in the treatment of cancer  
 INVENTOR(S): Barlaam, Bernard Christophe  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 90pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063291	A1	20070607	WO 2006-GB4447	20061129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1957499	A1	20080820	EP 2006-808705	20061129
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			EP 2005-292552	A 20051202
			EP 2006-290627	A 20060414
			WO 2006-GB4447	W 20061129

OTHER SOURCE(S): MARPAT 147:72781  
 GI



AB Quinazoline derivs. I are disclosed. I are medically useful by virtue of an antiproliferative effect, which is produced alone or in part by inhibiting erbB2 receptor tyrosine kinase in a warm-blooded animal such as man. In compds. I, R1 is H, OH, alkoxy, or alkoxyalkoxy; R2 and R3 are H, alk(en/yn)yl, or hydroxyalkyl; R4 and R5 are H, alk(en/yn)yl, or alkyl substituted with halo, cyano, OH, (di)(alkyl)amino, or alkoxy; or NR4R5 is saturated N/O/S heterocycle with a 4- to 7-membered ring and optionally substituted by halo, cyano, OH, alkyl, and/or alkoxy; R6 and R7 are H or halo; R8 and R9 are H, halo, cyano, alk(en/yn)yl, or alkoxy; Z is (CH<sub>2</sub>)<sub>0-3</sub> and its alkyl derivs.; Q is alkylthio, alkynyl, or a C-linked, saturated or partially unsatd. 4- to 7-membered heterocycle containing 1 or 2 O atoms and optional substituents selected from F, OH, alkoxy, and alkyl; wherein any heterocyclic NR4R5 or Q may bear 1 or 2 oxo or thioxo groups; including pharmaceutically acceptable salts. Eight examples are given. For instance, etherification of (R)-4-(2-hydroxypropionyl)morpholine with 2-chloro-4-[(5-fluoroquinazolin-4-yl)amino]phenol using NaH in DMA (47%), followed by Mitsunobu reaction with tetrahydrofuran-2-ylmethanol (66%), gave invention compound II. In test for inhibition of protein phosphorylation, II was selective for erbB2 tyrosine kinase over EGFR tyrosine kinase, with IC<sub>50</sub> values of 0.008 and 0.362 μM, resp. II also inhibited proliferation of BT474C human mammary carcinoma cells in vitro, with an IC<sub>50</sub> of 0.337 μM.

IT 940008-97-9P 940008-98-0P 940008-99-1P


RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; preparation of anilino-substituted quinazolines as tyrosine kinase inhibitors and antiproliferatives)

RN 940008-97-9 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX

NAME)


Absolute stereochemistry.



RN 940008-98-0 CAPLUS

CN Propanamide, 2-[4-[(3-chloro-4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl)amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 940008-99-1 CAPLUS

CN Propanamide, 2-[4-[(3-chloro-4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl)amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




IT 940009-01-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of anilino-substituted quinazolines as tyrosine kinase inhibitors and antiproliferatives)

RN 940009-01-8 CAPLUS

CN Propanamide, N-[2-(acetyloxy)ethyl]-N-methyl-2-[[4-[[3-methyl-4-[(tetrahydro-2H-pyran-2-yl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:618627 CAPLUS

DOCUMENT NUMBER: 147:31138

TITLE: Preparation of quinazolines as inhibitors of erbB2 receptor tyrosine kinase

INVENTOR(S): Bradbury, Robert Hugh; Barlaam, Bernard Christophe; Ducray, Richard

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 79pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007063293	A1	20070607	WO 2006-GB4451	20061129
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1960371	A1	20080827	EP 2006-820361	20061129
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			EP 2005-292551	A 20051202
			WO 2006-GB4451	W 20061129

OTHER SOURCE(S): MARPAT 147:31138  
GI

- AB Title compds. [I; R1 = H, OH, alkoxy, alkoxyalkoxy; R2, R3 = H, alkyl, alkenyl, alkynyl, hydroxyalkyl; R4, R5 = H, alkenyl, alkynyl, (substituted) alkyl; NR4R5 = 4-7 membered (substituted) heterocyclyl; G1, G2 = H, halo; G3, G4 = H, halo, cyano, alkyl, alkoxy, alkenyl, alkynyl; Q1 = atoms to form a 4-8 membered (unsatd.) (substituted) heterocyclyl], were prepared Thus, (2R)-2-[4-[(4-(azepan-1-ylcarbonyl)-3-chlorophenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide [preparation from (R)-lactamide, 5-fluoroquinazolin-4(3H)-one, 2-methylaminoethanol, 4-amino-2-chlorobenzoic acid, and azepane given] inhibited proliferation of BT474C cells with IC50 = 0.179 μM.
- IT 939427-43-7P 939427-44-8P 939427-45-9P  
939427-46-0P 939427-47-1P 939427-48-2P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(claimed compound; preparation of quinazolines as inhibitors of erbB2 tyrosine kinase)
- RN 939427-43-7 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-[(hexahydro-1H-azepin-1-yl)carbonyl]phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 939427-44-8 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(1-piperidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 939427-45-9 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(1-pyrrolidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 939427-46-0 CAPLUS

CN Propanamide, 2-[4-[(3-chloro-4-[(hexahydro-1H-azepin-1-yl)carbonyl]phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 939427-47-1 CAPLUS

CN Propanamide, 2-[4-[(3-chloro-4-(1-piperidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 939427-48-2 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(1-pyrrolidinylcarbonyl)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




IT 939427-49-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of quinazolines as inhibitors of erbB2 tyrosine kinase)

RN 939427-49-3 CAPLUS

CN Glycine, N-[(2R)-2-[[4-[[3-chloro-4-[(hexahydro-1H-azepin-1-yl)carbonyl]phenyl]amino]-5-quinazolinyl]oxy]-1-oxopropyl]-N-methyl-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1313931 CAPLUS

DOCUMENT NUMBER: 144:36370

TITLE: Preparation of 4-anilino-5-carbamoylmethoxyquinazolines as selective erbB2 receptor tyrosine kinase inhibitors for use against tumors

INVENTOR(S): Bradbury, Robert Hugh; Kettle, Jason Grant; Scott, James Stewart; Barlaam, Bernard Christophe

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca Uk Limited

SOURCE: PCT Int. Appl., 268 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:



English

FAMILY ACC. NUM. COUNT:

1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118572	A1	20051215	WO 2005-GB2215	20050602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005250224	A1	20051215	AU 2005-250224	20050602
CA 2567832	A1	20051215	CA 2005-2567832	20050602
EP 1756088	A1	20070228	EP 2005-747243	20050602
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1993349	A	20070704	CN 2005-80025966	20050602
BR 2005011741	A	20080102	BR 2005-11741	20050602
JP 2008501675	T	20080124	JP 2007-514135	20050602
IN 2006DN07220	A	20070824	IN 2006-DN7220	20061130
US 20070232607	A1	20071004	US 2006-628011	20061130
MX 2006PA14125	A	20070131	MX 2006-PA14125	20061204
NO 2006006081	A	20070220	NO 2006-6081	20061229
KR 2007038500	A	20070410	KR 2007-700221	20070104
PRIORITY APPLN. INFO.:			EP 2004-291393	A 20040604
			WO 2005-GB2215	W 20050602
OTHER SOURCE(S):	CASREACT 144:36370; MARPAT 144:36370			
GI				



AB The invention concerns 4-anilino-5-carbamoylmethoxyquinazolines (shown as I; variables defined below; e.g. 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide (shown as II)), processes for their preparation, pharmaceutical compns. containing them and their

use in the manufacture of a medicament for use as an antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of erbB2 receptor tyrosine kinases. For I: m = 0-2; each R1 = hydroxy, (1-6C)alkoxy, (3-7C)cycloalkyloxy and (3-7C)cycloalkyl(1-6C)alkoxy; R2 = H or (1-4C)alkyl; n = 0-4; each R3 = halo, cyano, (1-4C)alkyl, trifluoromethyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl; X1 = O, S, SO, SO2, N(R13), CH(OR13), CON(R13), N(R13)CO, SO2N(R13), N(R13)SO2, OC(R13)2, C(R13)2O, SC(R13)2, C(R13)2S, CO, C(R13)2N(R13) and N(R13)C(R13)2 (R13= H or (1-6C)alkyl); Q1 = (un)substituted aryl or heteroaryl. R4 and R5, which may be the same or different, = H and (1-6C)alkyl, or R4 and R5 together with the C atom to which they are attached form a (3-7C)cycloalkyl ring; R6 and R7, which may be the same or different, = H, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-7C)cycloalkyl, (3-7C)cycloalkyl(1-6C)alkyl, (3-7C)cycloalkenyl, (3-7C)cycloalkenyl(1-6C)alkyl, heterocyclyl and heterocyclyl(1-6C)alkyl, or R6 and R7 together with the N atom to which they are attached form a saturated 4-7 membered heterocyclic ring which optionally contains ≥1 addnl. heteroatoms = O, S, SO, SO2 and NR10; addnl. details are given in the claims. Methods of preparation are claimed and preps. and/or characterization data for .apprx.180 examples of I are included. For example, II was prepared in 13% yield by condensation of 2-bromoacetamide with 4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-ol (preparation given) in DMA in the presence of K2CO3 using 5 min of ultrasound treatment. IC50 values for inhibition of EGFR and erbB2 tyrosine kinase protein phosphorylation are tabulated for 4 examples of I.

IT 871018-52-9P, 2-[[4-[[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871018-53-0P

, 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methylsulfonylethyl)acetamide 871018-56-3P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-cyclopropylacetamide 871018-57-4P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-cyclobutylacetamide 871018-58-5P, 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methoxyethyl)acetamide 871018-59-6P, 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-ethylacetamide 871018-60-9P, N-Allyl-2-[[4-[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]acetamide 871018-61-0P  
 , 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-ethyl-N-methylacetamide 871018-62-1P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[2-(morpholin-4-yl)ethyl]acetamide 871018-65-4P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methyl-N-prop-2-ynylacetamide 871018-67-6P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylacetamide 871018-68-7P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methylsulfonylethyl)-N-methylacetamide 871018-69-8P  
 , 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methyl-N-(1-methylpiperidin-4-yl)acetamide 871018-70-1P  
 , 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-isopropyl-N-methylacetamide 871018-71-2P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-dimethylaminoethyl)-N-methylacetamide 871018-75-6P,  
 (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871018-77-8P, (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide 871018-78-9P, (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide 871018-80-3P, (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871018-86-9P,  
 (2S)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871018-89-2P, (2S)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide 871018-90-5P, (2S)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide 871018-91-6P, (2S)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871018-95-0P,  
 (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N-methylbutanamide 871018-96-1P,  
 (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N-(2-hydroxy-1,1-dimethylethyl)butanamide 871018-97-2P, (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N,N-dimethylbutanamide 871018-98-3P, (2R)-2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-4-hydroxy-N-(2-hydroxyethyl)-N-methylbutanamide 871019-02-2P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-2-methylpropanamide 871019-03-3P, 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methyl-2-methylpropanamide 871019-06-6P, 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxy-1,1-dimethylethyl)-2-methylpropanamide 871019-07-7P,  
 2-[[4-[3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-2-methylpropanamide 871019-08-8P,

2-[4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-5-yl]oxy]-N,N-bis(2-hydroxyethyl)-2-methylpropanamide 871019-09-9P  
 , 2-[4-[(3-Chloro-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methyl-2-methylpropanamide  
 871019-11-3P, N-(2-Hydroxyethyl)-2-methyl-2-[[4-[(3-methyl-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-16-8P, N-Methyl-2-methyl-2-[[4-[(3-methyl-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-17-9P, 2-[[4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]acetamide 871019-22-6P,  
 N-(2-Hydroxyethyl)-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]acetamide 871019-23-7P,  
 N-Methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]acetamide 871019-24-8P,  
 N-(2-Hydroxyethyl)-N-methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]acetamide 871019-28-2P,  
 (2S)-2-[[4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-31-7P, (2R)-2-[[4-[(3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-34-0P, (2R)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-35-1P, 2-Methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-38-4P  
 , N-Methyl-2-methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-41-9P  
 , (2R)-N-Methyl-2-[[4-[(3-methyl-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-42-0P, (2R)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[(3-methyl-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-44-2P, 2-Methyl-2-[[4-[(3-methyl-4-[(pyridin-2-yl)methoxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-45-3P, N-(2-Hydroxyethyl)-2-methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-46-4P, N-(2-Hydroxyethyl)-N-methyl-2-methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-48-6P, (2S)-N-(2-Hydroxyethyl)-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-49-7P, (2S)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide  
 871019-54-4P, (2R)-N-Methyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-55-5P  
 , (2R)-N-(2-Hydroxyethyl)-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-56-6P  
 , (2R)-N,N-Dimethyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-57-7P  
 , (2R)-N-Isopropyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-58-8P  
 , (2R)-N-Ethyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-59-9P  
 , (2R)-N-[2-(Diethylamino)ethyl]-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-60-2P  
 , (2R)-N-[2-(Dimethylamino)ethyl]-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-61-3P  
 , (2R)-N-Cyclopropyl-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-62-4P  
 , (2R)-N-(3-Hydroxypropyl)-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide 871019-63-5P  
 , (2R)-N-(2-Methoxyethyl)-2-[[4-[(3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl)amino]quinazolin-5-yl]oxy]propanamide

yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-64-6P  
 , (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[2-(morpholin-4-  
 yl)ethyl]propanamide 871019-65-7P, (2R)-2-[[4-[[3-Methyl-4-[(6-  
 methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[2-(pyrrolidin-  
 1-yl)ethyl]propanamide 871019-66-8P, (2R)-N-[2-  
 (Acetylamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-67-9P  
 , (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[3-(4-methylpiperazin-1-  
 yl)propyl]propanamide 871019-68-0P, (2R)-2-[[4-[[3-Methyl-4-[(6-  
 methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-[3-(2-  
 oxopyrrolidin-1-yl)propyl]propanamide 871019-69-1P,  
 (2R)-2-[[4-[[3-Methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-  
 5-yl]oxy]-N-[2-(methylthio)ethyl]propanamide 871019-70-4P,  
 (2R)-N-(3-Methoxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-71-5P  
 , (2R)-N-Cyclobutyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-72-6P  
 , (2R)-N-((2R)-2-Hydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-73-7P  
 , (2R)-N-((2S)-2-Hydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-74-8P  
 , (2R)-N-((2S)-2,3-Dihydroxypropyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-75-9P  
 , (2R)-N-((1R)-2-Hydroxy-1-methylethyl)-2-[[4-[[3-methyl-4-[(6-  
 methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide  
 871019-76-0P, (2R)-N-((1S)-2-Hydroxy-1-methylethyl)-2-[[4-[[3-  
 methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-  
 yl]oxy]propanamide 871019-78-2P, (2R)-N-[2-(Dimethylamino)ethyl]-  
 N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-83-9P  
 , (2R)-N,N-Bis(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-84-0P  
 , (2R)-N-Ethyl-N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-85-1P  
 , (2R)-N,N-Bis(2-methoxyethyl)-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-96-4P  
 , (2R)-N-(2-Methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-97-5P  
 , (2R)-N,N-Diethyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871019-99-7P  
 , (2R)-N-(3-Hydroxypropyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-45-0P  
 , (2R)-N-(2-Hydroxyethyl)-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide  
 871020-50-7P, (2R)-2-[[4-[[3-Methoxy-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide  
 871020-51-8P, (2R)-N-Ethyl-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-52-9P  
 , (2R)-N-(2-Hydroxyethyl)-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-55-2P  
 , (2R)-N-(2-Methoxyethyl)-2-[[4-[[3-methoxy-4-[(6-methylpyridin-3-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-methylpropanamide  
 871020-60-9P, (2R)-N,N-Dimethyl-2-[[4-[[3-methyl-4-[(pyridin-2-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-61-0P  
 , (2R)-N-Ethyl-2-[[4-[[3-methyl-4-[(pyridin-2-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-62-1P  
 , (2R)-N-(2-Hydroxyethyl)-2-[[4-[[3-methyl-4-[(pyridin-2-  
 yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-63-2P


, (2R)-N-(2-Hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-69-8P  
 , (2R)-N-(2-Methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871020-90-5P  
 , (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide 871020-91-6P,  
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871020-92-7P,  
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)propanamide 871020-93-8P,  
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-ethyl-N-(2-hydroxyethyl)propanamide 871021-02-2P,  
 (2R)-2-[[4-[[3-Chloro-4-[(pyridin-2-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-methoxyethyl)-N-methylpropanamide 871021-07-7P,  
 (2S)-N,N-Dimethyl-2-[[4-[[3-methyl-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]propanamide 871021-08-8P  
 , (2R)-2-[[4-[[3-Chloro-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N-(2-hydroxyethyl)-N-methylpropanamide 871021-12-4P, (2R)-2-[[4-[[3-Chloro-4-[(6-methylpyridin-3-yl)oxy]phenyl]amino]quinazolin-5-yl]oxy]-N,N-dimethylpropanamide

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of 4-anilino-5-carbamoylmethoxyquinazolines as selective erbB2 receptor tyrosine kinase inhibitors for use against tumors)


RN 871018-52-9 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871018-53-0 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 871018-56-3 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-cyclopropyl- (CA INDEX NAME)




RN 871018-57-4 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-cyclobutyl- (CA INDEX NAME)




RN 871018-58-5 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 871018-59-6 CAPLUS

CN Acetamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-ethyl- (CA INDEX NAME)




RN 871018-60-9 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-2-propen-1-yl- (CA INDEX NAME)




RN 871018-61-0 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-ethyl-N-methyl- (CA INDEX NAME)




RN 871018-62-1 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)




RN 871018-65-4 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-2-propyn-1-yl- (CA INDEX NAME)




RN 871018-67-6 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl- (CA INDEX NAME)




RN 871018-68-7 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-[2-(methylsulfonyl)ethyl]- (CA INDEX NAME)




RN 871018-69-8 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 871018-70-1 CAPLUS

CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)



RN 871018-71-2 CAPLUS


CN Acetamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(dimethylamino)ethyl]-N-methyl- (CA INDEX NAME)



RN 871018-75-6 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-77-8 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-78-9 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-80-3 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-86-9 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-89-2 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-90-5 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-91-6 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-95-0 CAPLUS

CN Butanamide, 2-[[4-[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-96-1 CAPLUS

CN Butanamide, 2-[[4-[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N-(2-hydroxy-1,1-dimethylethyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-97-2 CAPLUS

CN Butanamide, 2-[[4-[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871018-98-3 CAPLUS


Butanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-4-hydroxy-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)

## Absolute stereochemistry.




RN 871019-02-2 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-2-methyl- (CA INDEX NAME)




RN 871019-03-3 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,2-dimethyl- (CA INDEX NAME)




RN 871019-06-6 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxy-1,1-dimethylethyl)-2-methyl- (CA INDEX NAME)




RN 871019-07-7 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-2-methyl- (CA INDEX NAME)




RN 871019-08-8 CAPLUS

CN Propanamide, 2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-bis(2-hydroxyethyl)-2-methyl- (CA INDEX NAME)




RN 871019-09-9 CAPLUS

CN Propanamide, 2-[4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy-N-(2-hydroxyethyl)-N,2-dimethyl- (CA INDEX NAME)




RN 871019-11-3 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-methyl-2-[4-[(3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy- (CA INDEX NAME)




RN 871019-16-8 CAPLUS

CN Propanamide, N,2-dimethyl-2-[[4-[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871019-17-9 CAPLUS

CN Acetamide, 2-[[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871019-22-6 CAPLUS

CN Acetamide, N-(2-hydroxyethyl)-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871019-23-7 CAPLUS

CN Acetamide, N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-24-8 CAPLUS


CN Acetamide, N-(2-hydroxyethyl)-N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-28-2 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-31-7 CAPLUS

CN Propanamide, 2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-34-0 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-35-1 CAPLUS


CN Propanamide, 2-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-38-4 CAPLUS


CN Propanamide, N,2-dimethyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-41-9 CAPLUS

CN Propanamide, N-methyl-2-[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-42-0 CAPLUS


CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[(4-[(3-methyl-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-44-2 CAPLUS

CN Propanamide, 2-methyl-2-[(4-[(3-methyl-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]- (CA INDEX NAME)




RN 871019-45-3 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-46-4 CAPLUS


CN Propanamide, N-(2-hydroxyethyl)-N,2-dimethyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]- (CA INDEX NAME)



RN 871019-47-5 CAPLUS

CN Propanamide, N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-48-6 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-49-7 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-54-4 CAPLUS

CN Propanamide, N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-55-5 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-56-6 CAPLUS

CN Propanamide, N,N-dimethyl-2-[(4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-57-7 CAPLUS

CN Propanamide, N-(1-methylethyl)-2-[(4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-58-8 CAPLUS

CN Propanamide, N-ethyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-59-9 CAPLUS

CN Propanamide, N-[2-(diethylamino)ethyl]-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-60-2 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-61-3 CAPLUS

CN Propanamide, N-cyclopropyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-62-4 CAPLUS

CN Propanamide, N-(3-hydroxypropyl)-2-[(4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl)oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-63-5 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-2-[(4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-64-6 CAPLUS

CN Propanamide, 2-[4-[(3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(4-morpholinyl)ethyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-65-7 CAPLUS

CN Propanamide, 2-[4-[(3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(1-pyrrolidinyl)ethyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-66-8 CAPLUS

CN Propanamide, N-[2-(acetylamino)ethyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-67-9 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[3-(4-methyl-1-piperazinyl)propyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-68-0 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-69-1 CAPLUS

CN Propanamide, 2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-[2-(methylthio)ethyl]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-70-4 CAPLUS

CN Propanamide, N-(3-methoxypropyl)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-71-5 CAPLUS

CN Propanamide, N-cyclobutyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-72-6 CAPLUS

CN Propanamide, N-[(2R)-2-hydroxypropyl]-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-73-7 CAPLUS

CN Propanamide, N-[(2S)-2-hydroxypropyl]-2-[4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-74-8 CAPLUS

CN Propanamide, N-[(2S)-2,3-dihydroxypropyl]-2-{[4-[(3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino)-5-quinazolinyl]oxy}]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-75-9 CAPLUS

CN Propanamide, N-[(1R)-2-hydroxy-1-methylethyl]-2-{[4-[(3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino)-5-quinazolinyl]oxy}]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-76-0 CAPLUS

CN Propanamide, N-[(1S)-2-hydroxy-1-methylethyl]-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-78-2 CAPLUS

CN Propanamide, N-[2-(dimethylamino)ethyl]-N-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-83-9 CAPLUS

CN Propanamide, N,N-bis(2-hydroxyethyl)-2-[ [4-[ [3-methyl-4-[ (6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-84-0 CAPLUS

CN Propanamide, N-ethyl-N-(2-hydroxyethyl)-2-[ [4-[ [3-methyl-4-[ (6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-85-1 CAPLUS

CN Propanamide, N,N-bis(2-methoxyethyl)-2-[ [4-[ [3-methyl-4-[ (6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-96-4 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871019-97-5 CAPLUS

CN Propanamide, N,N-diethyl-2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871019-99-7 CAPLUS

CN Propanamide, N-(3-hydroxypropyl)-N-methyl-2-[4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-45-0 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[4-[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-50-7 CAPLUS

CN Propanamide, 2-[4-[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-51-8 CAPLUS

CN Propanamide, N-ethyl-2-[4-[[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-52-9 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[4-[[3-methoxy-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871020-55-2 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-2-[4-[[3-methoxy-4-[(6-methyl-3-

pyridinyl]oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-60-9 CAPLUS

CN Propanamide, N,N-dimethyl-2-[4-[[3-methyl-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-61-0 CAPLUS

CN Propanamide, N-ethyl-2-[4-[[3-methyl-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-62-1 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-2-[[4-[[3-methyl-4-(2-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-63-2 CAPLUS

CN Propanamide, N-(2-hydroxyethyl)-N-methyl-2-[[4-[[3-methyl-4-(2-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871020-69-8 CAPLUS

CN Propanamide, N-(2-methoxyethyl)-N-methyl-2-[[4-[[3-methyl-4-(2-

pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-90-5 CAPLUS

CN Propanamide, 2-[4-[(3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-91-6 CAPLUS

CN Propanamide, 2-[4-[(3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-92-7 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871020-93-8 CAPLUS

CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-ethyl-N-(2-hydroxyethyl)-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871021-02-2 CAPLUS


CN Propanamide, 2-[[4-[[3-chloro-4-(2-pyridinyloxy)phenyl]amino]-5-quinazolinyl]oxy]-N-(2-methoxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 871021-07-7 CAPLUS  
 CN Propanamide, N,N-dimethyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 871021-08-8 CAPLUS  
 CN Propanamide, 2-[[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]-N-(2-hydroxyethyl)-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 871021-12-4 CAPLUS  
 CN Propanamide, 2-[[4-[[3-chloro-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-

quinazolinyl]oxy]-N,N-dimethyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:490358 CAPLUS  
 DOCUMENT NUMBER: 143:43897  
 TITLE: Preparation of quinazoline derivatives as erbB2 receptor tyrosine kinase inhibitors  
 INVENTOR(S): Bradbury, Robert Hugh; Hennequin, Laurent Francois Andre; Kettle, Jason Grant  
 PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SOURCE: PCT Int. Appl., 286 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005051923	A1	20050609	WO 2004-GB4761	20041111
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004293250	A1	20050609	AU 2004-293250	20041111
CA 2545262	A1	20050609	CA 2004-2545262	20041111
EP 1685116	A1	20060802	EP 2004-798484	20041111
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
CN 1906178	A	20070131	CN 2004-80040415	20041111
BR 2004016479	A	20070306	BR 2004-16479	20041111
JP 2007511491	T	20070510	JP 2006-538946	20041111

MX 2006PA05364	A	20060731	MX 2006-PA5364	20060512
NO 2006002353	A	20060809	NO 2006-2353	20060523
IN 2006DN03254	A	20070824	IN 2006-DN3254	20060606
US 20070244136	A1	20071018	US 2007-578663	20070117
PRIORITY APPLN. INFO.:			GB 2003-26459	A 20031113
			WO 2004-GB4761	W 20041111

OTHER SOURCE(S): CASREACT 143:43897; MARPAT 143:43897  
GI



I



II

AB Title compds. I [ $m = 0-2$ ; R1 independently = OH, (un)substituted-alkoxy, -cycloalkyloxy, etc.; R2 = H, alkyl; n = 0-4; R3 independently = CN, halo, CF<sub>3</sub>, etc.; X = O, S, SO, etc.; Q = (un)substituted-aryl, -heteroaryl; R4, R4a, R5a independently = H, (un)substituted-alkyl, or R4 and R4a together = 3- to 7-membered (un)substituted cycloalkyl ring or R5 and R5a together = 3- to 7-membered (un)substituted cycloalkyl ring; R6 = H, alkenyl, alkynyl, etc.; A = H, Z-(CR<sub>7</sub>R<sub>8</sub>)p-, R<sub>9</sub>; p = 1-4; R<sub>7</sub> and R<sub>8</sub> independently = H, alkyl, alkenyl, etc. or R<sub>7</sub> and R<sub>8</sub> together = (un)substituted-3- to 7-membered-cycloalkyl or -cycloalkenyl ring; Z = H, alkylsulfonyl, alkanesulfonylamino, etc.; R<sub>9</sub> = H, OR<sub>10</sub>, NR<sub>11</sub>R<sub>12</sub>, etc.; R<sub>10</sub> = alkyl, alkenyl, alkynyl; R<sub>11</sub> and R<sub>12</sub> independently = H, alkyl, alkoxy carbonyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of erbB2 receptor tyrosine kinase. Thus, e.g., II was prepared by chlorination of 5-fluoro-3,4-dihydro-3H-quinazolin-4-one followed by amination with 3-chloro-4-(2-pyridylmethoxy)aniline to give N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-fluoroquinazolin-4-amine (III). III was then converted into the resp. 5-(2-methylamino)ethoxy ether intermediate using 2-(methylamino)ethanol and subsequent acetylation of this intermediate yielded II. The inhibitory activity of I was evaluated using phosphorylation assays of

erbB2 tyrosine kinase and it revealed that selected compds. of the invention displayed IC<sub>50</sub> values in the range of 0.002 up to 0.017 μM. I as inhibitors of erbB2 receptor tyrosine kinase should prove useful as antitumor agents. Pharmaceutical compns. comprising I are disclosed.


IT 853000-27-8P 853000-28-9P 853000-29-0P  
 853000-30-3P 853000-31-4P 853000-32-5P  
 853000-33-6P 853000-34-7P 853000-35-8P  
 853000-36-9P 853000-37-0P 853000-38-1P  
 853000-39-2P 853000-40-5P 853000-41-6P  
 853000-42-7P 853000-43-8P 853000-44-9P  
 853000-45-0P 853000-46-1P 853000-47-2P  
 853000-48-3P 853000-49-4P 853000-50-7P  
 853000-51-8P 853000-52-9P 853000-53-0P  
 853000-54-1P 853000-55-2P 853000-56-3P  
 853000-57-4P 853000-58-5P 853000-59-6P  
 853000-60-9P 853000-61-0P 853000-62-1P  
 853000-63-2P 853000-64-3P 853000-65-4P  
 853000-66-5P 853000-67-6P 853000-68-7P  
 853000-69-8P 853000-70-1P 853000-72-3P  
 853000-73-4P 853000-74-5P 853000-75-6P  
 853000-76-7P 853000-77-8P 853000-78-9P  
 853000-79-0P 853000-80-3P 853000-81-4P  
 853000-82-5P 853000-83-6P 853000-84-7P  
 853000-85-8P 853000-86-9P 853000-87-0P  
 853000-88-1P 853000-89-2P 853000-90-5P  
 853000-91-6P 853000-92-7P 853000-93-8P  
 853000-94-9P 853000-95-0P 853000-96-1P  
 853000-97-2P 853000-98-3P 853000-99-4P  
 853001-00-0P 853001-01-1P 853001-02-2P  
 853001-03-3P 853001-04-4P 853001-05-5P  
 853001-06-6P 853001-07-7P 853001-08-8P  
 853001-09-9P 853001-10-2P 853001-11-3P  
 853001-12-4P 853001-13-5P 853001-14-6P  
 853001-15-7P 853001-16-8P 853001-17-9P  
 853001-18-0P 853001-19-1P 853001-20-4P  
 853001-21-5P 853001-22-6P 853001-23-7P  
 853001-24-8P 853001-25-9P 853001-26-0P  
 853001-27-1P 853001-28-2P 853001-29-3P  
 853001-30-6P 853001-31-7P 853001-32-8P  
 853001-33-9P 853001-34-0P 853001-35-1P  
 853001-36-2P 853001-37-3P 853001-38-4P  
 853001-39-5P 853001-41-9P 853001-42-0P  
 853001-43-1P 853001-44-2P 853001-45-3P  
 853001-46-4P 853001-47-5P 853001-48-6P  
 853001-49-7P 853001-50-0P 853001-51-1P  
 853001-52-2P 853001-53-3P 853001-54-4P  
 853001-55-5P 853001-56-6P 853001-57-7P  
 853001-58-8P 853001-59-9P 853001-60-2P  
 853001-61-3P 853001-62-4P 853001-63-5P  
 853001-64-6P 853001-65-7P 853001-66-8P  
 853001-67-9P 853001-68-0P 853001-69-1P  
 853001-70-4P 853001-71-5P 853001-72-6P  
 853001-73-7P 853001-74-8P 853001-75-9P  
 853001-76-0P 853001-77-1P 853001-78-2P  
 853001-79-3P 853001-80-6P 853193-87-0P, AZ

12240261


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of quinazoline derivs. as erbB2 receptor tyrosine kinase


inhibitors)  
RN 853000-27-8 CAPLUS  
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 853000-28-9 CAPLUS  
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-methoxy-N-methyl- (CA INDEX NAME)




RN 853000-29-0 CAPLUS  
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)



RN 853000-30-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-31-4 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-32-5 CAPLUS


CN Acetamide, N-[{(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl}-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 853000-33-6 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853000-34-7 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-35-8 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853000-36-9 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853000-37-0 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853000-38-1 CAPLUS


CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853000-39-2 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-40-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)




RN 853000-41-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)




RN 853000-42-7 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)




RN 853000-43-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



RN 853000-44-9 CAPLUS


CN Acetamide, N-[2-[(4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



RN 853000-45-0 CAPLUS

CN Acetamide, N-[(2R)-2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-46-1 CAPLUS

CN Acetamide, N-[(2R)-2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-47-2 CAPLUS

CN Acetamide, N-[(2R)-2-[(4-[(3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-48-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-49-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-50-7 CAPLUS


CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-51-8 CAPLUS

CN Acetamide, N-[2-[4-[[3-chloro-4-[(6-methyl-2-pyridinyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853000-52-9 CAPLUS

CN Acetamide, N-[2-[4-[[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853000-53-0 CAPLUS

CN Acetamide, N-[2-[(4-[(3-chlorophenoxy)-4-(3-fluorophenyl)methoxy]phenyl)amino]-5-quinazolinyl]oxyethyl-N-methyl- (CA INDEX NAME)




RN 853000-54-1 CAPLUS

CN Acetamide, N-[2-[(4-[(3-chlorophenoxy)-4-(4-thiazolylmethoxy)phenyl)amino]-5-quinazolinyl]oxyethyl-N-methyl- (CA INDEX NAME)



RN 853000-55-2 CAPLUS


CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 853000-56-3 CAPLUS


CN Acetamide, N-[(2R)-2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-57-4 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-ethyl- (CA INDEX NAME)




RN 853000-58-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-ethyl-2-hydroxy- (CA INDEX NAME)




RN 853000-59-6 CAPLUS

CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]-N-propyl- (CA INDEX NAME)




RN 853000-60-9 CAPLUS


CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-propyl- (CA INDEX NAME)



RN 853000-61-0 CAPLUS  
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 853000-62-1 CAPLUS  
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(1-methylethyl)- (CA INDEX NAME)




RN 853000-63-2 CAPLUS

CN Acetamide, N-[2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-2-propen-1-yl- (CA INDEX NAME)




RN 853000-64-3 CAPLUS

CN Acetamide, N-[2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-2-propen-1-yl- (CA INDEX NAME)




RN 853000-65-4 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclopropyl- (CA INDEX NAME)




RN 853000-66-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-cyclopropyl-2-hydroxy- (CA INDEX NAME)




RN 853000-67-6 CAPLUS

CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]-N-(cyclopropylmethyl)- (CA INDEX NAME)




RN 853000-68-7 CAPLUS

CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]-N-(cyclopropylmethyl)-2-hydroxy- (CA INDEX NAME)




RN 853000-69-8 CAPLUS

CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]-N-cyclobutyl- (CA INDEX NAME)




RN 853000-70-1 CAPLUS

CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]-N-cyclobutyl-2-hydroxy- (CA INDEX NAME)




RN 853000-72-3 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 853000-73-4 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 853000-74-5 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)




RN 853000-75-6 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 853000-76-7 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 853000-77-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 853000-78-9 CAPLUS

CN Acetamide, N-[2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-(2-methoxyethyl)- (CA INDEX NAME)




RN 853000-79-0 CAPLUS

CN Acetamide, N-[2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-2-propyn-1-yl- (CA INDEX NAME)




RN 853000-80-3 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-2-propyn-1-yl- (CA INDEX NAME)




RN 853000-81-4 CAPLUS


CN Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



RN 853000-82-5 CAPLUS  
CN 2-Furancarboxamide, N-[2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyltetrahydro-N-methyl- (CA INDEX NAME)




RN 853000-83-6 CAPLUS  
CN 2-Pyrrolidinecarboxamide, N-[2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl-N,1-dimethyl- (CA INDEX NAME)




RN 853000-84-7 CAPLUS

CN Propanamide, N-[2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy-N,2-dimethyl- (CA INDEX NAME)




RN 853000-85-8 CAPLUS

CN Cyclopropanecarboxamide, N-[2-[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-1-hydroxy-N-methyl- (CA INDEX NAME)




RN 853000-86-9 CAPLUS

CN Acetamide, N-[2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl-2-(methylamino)- (CA INDEX NAME)



RN 853000-87-0 CAPLUS


CN Propanamide, N-[2-[(4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(hydroxyamino)-N,2-dimethyl- (CA INDEX NAME)



RN 853000-88-1 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-89-2 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-90-5 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-91-6 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-92-7 CAPLUS


CN Acetamide, N-[{(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(methylsulfonyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 853000-93-8 CAPLUS

CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-hydroxy- (CA INDEX NAME)




RN 853000-94-9 CAPLUS


CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(dimethylamino)- (CA INDEX NAME)



RN 853000-95-0 CAPLUS  
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-methoxy- (CA INDEX NAME)




RN 853000-96-1 CAPLUS  
CN Acetamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2-(methylsulfonyl)- (CA INDEX NAME)



RN 853000-97-2 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-98-3 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853000-99-4 CAPLUS

CN Acetamide, N-[ (2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-00-0 CAPLUS

CN Acetamide, N-[ (2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-01-1 CAPLUS

CN Acetamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl-2-(methylsulfonyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-02-2 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyrazinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-03-3 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-04-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amin o]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-05-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-[(2-fluorophenyl)methoxy]phenyl]amin o]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-06-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-07-7 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-08-8 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-09-9 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-10-2 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-methoxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-11-3 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-12-4 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-13-5 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-14-6 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-15-7 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-16-8 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-17-9 CAPLUS

CN Butanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-18-0 CAPLUS

CN Butanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-19-1 CAPLUS

CN Butanamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-20-4 CAPLUS

CN Butanamide, N-[(2S)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-21-5 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-22-6 CAPLUS

CN Butanamide, N-[(1R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-23-7 CAPLUS

CN Butanamide, N-[2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-24-8 CAPLUS

CN Butanamide, N-[2-[(4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-25-9 CAPLUS

CN Butanamide, N-[(1R)-2-[(4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-26-0 CAPLUS

CN Butanamide, N-[(1R)-2-[(4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-


quinazolinyl]oxy]-1-methylethyl]-2,4-dihydroxy-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-27-1 CAPLUS

CN Acetamide, N-methyl-N-[2-[(4-[(3-methyl-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-28-2 CAPLUS

CN Acetamide, N-methyl-N-[2-[(4-[(3-methyl-4-(4-thiazolylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-29-3 CAPLUS

CN Acetamide, N-methyl-N-[2-[[4-[[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-30-6 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-31-7 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-32-8 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-33-9 CAPLUS  
 CN Acetamide, N-[2-[(4-[(3-chloro-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]-1,1-dimethylethyl]-2-hydroxy- (CA INDEX NAME)



RN 853001-34-0 CAPLUS  
 CN Acetamide, 2-hydroxy-N-[(2R)-2-[(4-[(3-methyl-4-(2-pyridinylmethoxy)phenyl]amino)-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-35-1 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[(4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-36-2 CAPLUS

CN Acetamide, N-[(2R)-2-[(4-[[4-[(3-fluorophenyl)methoxy]-3-methylphenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-37-3 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-38-4 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-39-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-41-9 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[4-((3-methylphenyl)ethoxy)quinazolinyl]amino]phenyl]methoxy]methyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-42-0 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[[3-methyl-4-(2-thiazolylmethoxy)phenyl]amino]phenyl]methoxy]methyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-43-1 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-44-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-45-3 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-46-4 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-47-5 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-48-6 CAPLUS

CN Acetamide, N-[(1R)-2-[[4-[[3-chloro-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-49-7 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-50-0 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-(4-thiazolylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-51-1 CAPLUS

CN Cyclopropanecarboxamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-1-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-52-2 CAPLUS

CN Propanamide, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-53-3 CAPLUS

CN Propanamide, N-[ (2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-54-4 CAPLUS

CN Propanamide, N-[ (2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-55-5 CAPLUS

CN Propanamide, N-[ (2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-methoxy-N-methyl-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-56-6 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-57-7 CAPLUS

CN Acetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-58-8 CAPLUS

CN Acetamide, 2-(dimethylamino)-N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-59-9 CAPLUS

CN 1-Pyrrolidineacetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-60-2 CAPLUS

CN 4-Morpholineacetamide, N-methyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-61-3 CAPLUS

CN 1-Piperazineacetamide, N,4-dimethyl-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-62-4 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-63-5 CAPLUS

CN Acetamide, N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-

pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-64-6 CAPLUS

CN 1-Pyrrolidineacetamide, N-methyl-N-[(2S)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-65-7 CAPLUS


CN Butanamide, 2,4-dihydroxy-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-66-8 CAPLUS  
 CN Butanamide, 4-bromo-2-hydroxy-N-[(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 853001-67-9 CAPLUS  
 CN Urea, N-(2-chloroethyl)-N'-(2R)-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-68-0 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-69-1 CAPLUS

CN Acetamide, N-methyl-N-[(1R)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-70-4 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[(1S)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-71-5 CAPLUS


CN Acetamide, N-methyl-N-[(1S)-1-methyl-2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-72-6 CAPLUS


CN Carbamic acid, [2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 853001-73-7 CAPLUS  
CN Urea, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N,N'-dimethyl- (CA INDEX NAME)




RN 853001-74-8 CAPLUS  
CN Urea, N'-(2-chloroethyl)-N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 853001-75-9 CAPLUS

CN Urea, N-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-N'-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-76-0 CAPLUS

CN Carbamic acid, [2-[(2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]amino]-2-oxoethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-77-1 CAPLUS


CN Acetamide, N-[ (2R)-2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]propyl]-2-(methylamino)- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-78-2 CAPLUS

CN Acetamide, 2-hydroxy-N-methyl-N-[2-[[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-79-3 CAPLUS

CN Acetamide, N-methyl-N-[2-[4-[[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)




RN 853001-80-6 CAPLUS

CN Acetamide, N-[2-[4-[[3-chloro-4-[(1-methyl-1-(2-pyridinyl)ethoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 853193-87-0 CAPLUS

CN Propanamide, N-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]-3-hydroxy-N-methyl- (CA INDEX NAME)



IT 786689-48-3P 786689-66-5P 786689-86-9P

853001-81-7P 853001-82-8P 853001-84-0P

853001-85-1P 853001-86-2P 853001-87-3P

853001-88-4P 853001-89-5P 853001-90-8P

853001-91-9P 853001-92-0P 853001-93-1P

853001-94-2P 853001-95-3P 853001-96-4P

853001-97-5P 853002-00-3P 853002-01-4P

853002-02-5P 853002-03-6P 853002-04-7P

853002-05-8P 853002-06-9P 853002-07-0P

853002-08-1P 853002-09-2P 853002-10-5P

853002-11-6P 853002-12-7P 853002-13-8P

853002-14-9P 853002-15-0P 853002-16-1P

853002-17-2P 853002-18-3P 853002-19-4P  
 853002-20-7P 853002-21-8P 853002-22-9P  
 853002-23-0P 853002-24-1P 853002-25-2P  
 853002-26-3P 853002-27-4P 853002-28-5P  
 853002-29-6P 853002-30-9P 853002-31-0P  
 853002-32-1P 853002-33-2P 853002-34-3P  
 853002-35-4P 853002-36-5P 853002-37-6P  
 853002-38-7P 853002-39-8P 853002-40-1P  
 853002-41-2P 853002-42-3P 853002-43-4P  
 853002-44-5P 853002-45-6P 853002-46-7P  
 853002-47-8P 853002-48-9P 853002-49-0P  
 853002-50-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of quinazoline derivs. as erbB2 receptor tyrosine kinase inhibitors)

RN 786689-48-3 CAPLUS

CN Phenol, 4-[[5-[(1R)-2-amino-1-methylethoxy]-4-quinazolinyl]amino]-2-chloro-  
 (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-66-5 CAPLUS

CN Phenol, 4-[[5-[(1R)-2-amino-1-methylethoxy]-4-quinazolinyl]amino]-2-methyl-  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-86-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-1-


methyl-2-(methyl-2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853001-81-7 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(methylamino)ethoxy]- (CA INDEX NAME)



RN 853001-82-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[ (1R)-1-methyl-2-(methylamino)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-84-0 CAPLUS


CN 4-Quinazolinamine, 5-[(2R)-2-aminopropoxy]-N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-85-1 CAPLUS

CN 4-Quinazolinamine, 5-(2-aminoethoxy)-N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)




RN 853001-86-2 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)



RN 853001-87-3 CAPLUS


CN Phenol, 2-methyl-4-[(5-[(2-(methylamino)ethoxy]-4-quinazolinyl)amino]-2-methylphenyl)oxy]phenol (CA INDEX NAME)



RN 853001-88-4 CAPLUS


CN Acetamide, N-[(2R)-2-[(4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-89-5 CAPLUS

CN Phenol, 2-chloro-4-[(5-[(2-methylamino)ethoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)



RN 853001-90-8 CAPLUS


CN Acetamide, N-[(2-[(4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy)ethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)



RN 853001-91-9 CAPLUS

CN Acetamide, N-[{(2R)-2-[(4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl}- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-92-0 CAPLUS

CN Phenol, 2-chloro-4-[(5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-93-1 CAPLUS

CN Phenol, 2-chloro-4-[[5-[(1R)-1-methyl-2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-94-2 CAPLUS


CN Acetamide, N-[2R]-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 853001-95-3 CAPLUS

CN Acetamide, N-[2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853001-96-4 CAPLUS  
CN Acetamide, N-[{(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-hydroxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 853001-97-5 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(ethylamino)ethoxy]- (CA INDEX NAME)




RN 853002-00-3 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(propylamino)ethoxy]- (CA INDEX NAME)




RN 853002-01-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(1-methylethyl)amino]ethoxy]- (CA INDEX NAME)




RN 853002-02-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)




RN 853002-03-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(cyclopropylamino)ethoxy]- (CA INDEX NAME)




RN 853002-04-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(cyclopropylmethyl)amino]ethoxy- (CA INDEX NAME)




RN 853002-05-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(cyclobutylamino)ethoxy]- (CA INDEX NAME)




RN 853002-06-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(1-methyl-4-piperidinyl)amino]ethoxy]- (CA INDEX NAME)




RN 853002-07-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(tetrahydro-2H-pyran-4-yl)amino]ethoxy]- (CA INDEX NAME)




RN 853002-08-1 CAPLUS

CN Ethanol, 2-[[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]amino]- (CA INDEX NAME)




RN 853002-09-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-[(2-methoxyethyl)amino]ethoxy]- (CA INDEX NAME)



RN 853002-10-5 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(2-propynylamino)ethoxy]- (CA INDEX NAME)



RN 853002-11-6 CAPLUS

CN 4-Quinazolinamine, 5-[(1S)-2-amino-1-methylethoxy]-N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-12-7 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-13-8 CAPLUS

CN Acetamide, N-[(1R)-2-[(4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-14-9 CAPLUS

CN Phenol, 2-chloro-4-[(5-[(2R)-2-(methylamino)propoxy]-4-quinazolinyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-15-0 CAPLUS

CN Acetamide, N-[(1R)-2-[(4-[(3-chloro-4-hydroxyphenyl)amino]-5-

quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-16-1 CAPLUS

CN Acetamide, N-[(1S)-2-[(4-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-17-2 CAPLUS

CN Phenol, 2-chloro-4-[(2S)-2-(methylamino)propoxy]-4-quinazolinyl]amino- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-18-3 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-19-4 CAPLUS

CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-methoxy-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-20-7 CAPLUS


CN Acetamide, N-[(1S)-2-[[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-2-hydroxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-21-8 CAPLUS  
CN Phenol, 4-[5-[(2S)-2-aminopropoxy]-4-quinazolinyl]amino]-2-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 853002-22-9 CAPLUS  
CN Acetamide, N-[(1S)-2-[(4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl)oxy]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-23-0 CAPLUS  
CN 4-Quinazolinamine, 5-[(2S)-2-aminopropoxy]-N-[3-chloro-4-(2-

pyridinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-24-1 CAPLUS

CN Acetamide, N-[(2R)-2-[(4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]propyl]-2-(dimethylamino)- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-25-2 CAPLUS


CN 4-Quinazolinamine, 5-[(1R)-2-amino-1-methylethoxy]-N-[(3-chloro-4-(2-pyridinylmethoxy)phenyl)-] (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-26-3 CAPLUS

CN 4-Quinazolinamine, 5-(2-aminoethoxy)-N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)



RN 853002-27-4 CAPLUS


CN Phenol, 4-[(5-(2-aminoethoxy)-4-quinazolinyl)amino]-2-chloro- (CA INDEX NAME)



RN 853002-28-5 CAPLUS

CN 4-Quinazolinamine, 5-[(2R)-2-aminopropoxy]-N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-29-6 CAPLUS

CN Phenol, 4-[[5-[(2R)-2-aminopropoxy]-4-quinazolinyl]amino]-2-chloro- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-30-9 CAPLUS


CN Acetamide, N-[2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-

quinazolinyl]oxy]ethyl]-N-methyl- (CA INDEX NAME)




RN 853002-31-0 CAPLUS

CN Acetamide, 2-hydroxy-N-[2-[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]ethyl]- (CA INDEX NAME)



RN 853002-32-1 CAPLUS


CN Phenol, 4-[[5-(2-aminoethoxy)-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)



RN 853002-33-2 CAPLUS


CN Acetamide, N-[2-[4-[(3-chloro-4-hydroxyphenyl)amino]-5-quinazolinyl]oxy]-

1,1-dimethylethyl]-2-hydroxy- (CA INDEX NAME)



RN 853002-34-3 CAPLUS


CN Phenol, 4-[5-(2-amino-2-methylpropoxy)-4-quinazolinyl]amino]-2-chloro- (CA INDEX NAME)



RN 853002-35-4 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-36-5 CAPLUS

CN Acetamide, N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-37-6 CAPLUS

CN Acetamide, 2-hydroxy-N-[(2R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]propyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-38-7 CAPLUS


CN Phenol, 2-methyl-4-[[5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-39-8 CAPLUS  
 CN Phenol, 2-methyl-4-[5-[(1R)-1-methyl-2-(methylamino)ethoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 853002-40-1 CAPLUS  
 CN Acetamide, N-[(1R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-41-2 CAPLUS  
 CN Phenol, 2-methyl-4-[5-[(2R)-2-(methylamino)propoxy]-4-quinazolinyl]amino]-

(CA INDEX NAME)


Absolute stereochemistry.



RN 853002-42-3 CAPLUS

CN Acetamide, 2-hydroxy-N-[(1R)-2-[[4-[(4-hydroxy-3-methylphenyl)amino]-5-quinazolinyl]oxy]-1-methylethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-43-4 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-1-methyl-2-(methylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-44-5 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-45-6 CAPLUS

CN 4-Quinazolinamine, 5-[(1S)-1-methyl-2-(methylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-46-7 CAPLUS

CN 4-Quinazolinamine, 5-[(1S)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-47-8 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-amino-1-methylethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 853002-48-9 CAPLUS

CN 4-Quinazolinamine, 5-[(2R)-2-(methylamino)propoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 853002-49-0 CAPLUS

CN 4-Quinazolinamine, 5-[(2S)-2-(methylamino)propoxy]-N-[3-methyl-4-[(6-


(CA INDEX NAME)

Absolute stereochemistry.



RN 853002-50-3 CAPLUS

CN 4-Quinazolinamine, 5-[2-(methylamino)ethoxy]-N-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]phenyl]- (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:927050 CAPLUS

DOCUMENT NUMBER: 141:395568

TITLE: Preparation of (anilino)quinazoline derivatives as antiproliferative agents

INVENTOR(S): Bradbury, Robert Hugh; Kettle, Jason Grant

PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited

SOURCE: PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004093880	A1	20041104	WO 2004-GB1713	20040420
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004231349	A1	20041104	AU 2004-231349	20040420
CA 2526897	A1	20041104	CA 2004-2526897	20040420
EP 1631292	A1	20060308	EP 2004-728367	20040420
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009633	A	20060425	BR 2004-9633	20040420
CN 1809360	A	20060726	CN 2004-80017046	20040420
JP 2006524218	T	20061026	JP 2006-506155	20040420
NZ 543015	A	20080131	NZ 2004-543015	20040420
NO 2005004856	A	20051121	NO 2005-4856	20051020
US 20070149546	A1	20070628	US 2005-554202	20051024
PRIORITY APPLN. INFO.:			GB 2003-9009	A 20030422
			WO 2004-GB1713	W 20040420

OTHER SOURCE(S):

MARPAT 141:395568

GI



AB Title compds. represented by the formula I [wherein R1, R2 = independently H, carboxy, formyl, etc.; R1a, R2a = independently H or alkyl; R3, R4 = independently H, alkyl, alkenyl; R5 = halo, OH, alkyl, alkoxy, alkenyl,

alkynyl; R6 = H, alkoxy, alkenyloxy, alkynyloxy; X = H, halo, alkyl, alkoxy, alkenyl, alkynyl; Y = O, S, SO<sub>2</sub>, etc.; Q1 = Ph, pyridinyl, pyrazinyl, etc.; and pharmaceutically acceptable salts thereof] were prepared as antiproliferative agents. For example, reaction of 2-chloro-4-[5-[(1R)-2-dimethylamino-1-methylethoxy]quinazolin-4-yl]amino]phenol with 4-(chloromethyl)thiazole•HCl gave II in 20% yield. II showed inhibition of phosphorylation of a tyrosine containing polypeptide substance by ERBB2 kinase (IC<sub>50</sub> = 0.002 μM), EGFR kinase (IC<sub>50</sub> = 0.068 μM) and ERBB2 in a MCF6 (breast carcinoma) derived cell line (IC<sub>50</sub> = 0.001 μM). Thus, I and their pharmaceutical compns. are useful as antiproliferative agents in the production of an ERBB2 receptor tyrosine kinase inhibitory effect in a warm-blooded animal such as man.

IT 786688-99-1P, 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-00-7P,  
 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-01-8P, 4-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-03-0P, 4-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]anilino]-5-(2-dimethylamino-2-methylethoxy)quinazoline 786689-04-1P, 4-[4-(3-Fluorobenzylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-06-3P,  
 4-[4-(3-Fluorobenzylmethoxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-07-4P, 4-[3-Chloro-4-(2-pyrazinylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-11-0P, 4-[3-Chloro-4-(2-pyrazinylmethoxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-12-1P,  
 4-[3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-15-4P,  
 4-[3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino]-5-(2-dimethylamino-1-methylethoxy)quinazoline 786689-16-5P, 4-[3-Chloro-4-(3-fluorobenzylmethoxy)anilino]-5-[2-(N-ethyl-N-methylamino)ethoxy]quinazoline 786689-17-6P 786689-21-2P, 4-[3-Chloro-4-(3-fluorobenzylmethoxy)anilino]-5-(2-dimethylaminoethoxy)quinazoline 786689-22-3P, 4-[3-Chloro-4-(3-fluorobenzylmethoxy)anilino]-5-[2-(N-(2-hydroxyethyl)-N-methylamino)ethoxy]quinazoline 786689-23-4P,  
 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-[2-(N-ethyl-N-methylamino)ethoxy]quinazoline 786689-24-5P 786689-28-9P,  
 , 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-[2-(N-(2-hydroxyethyl)-N-methylamino)ethoxy]quinazoline 786689-29-0P 786689-30-3P  
 , 4-[3-Chloro-4-(3-fluorobenzylmethoxy)anilino]-5-(2-dimethylamino-2-methylethoxy)quinazoline 786689-31-4P 786689-33-6P,  
 4-[3-Chloro-4-(2-pyridylmethoxy)anilino]-5-(2-dimethylamino-2-methylethoxy)quinazoline 786689-35-8P, N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylaminoethoxy]quinazolin-4-amine 786689-38-1P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylaminoethoxy]quinazolin-4-amine 786689-39-2P,  
 N-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-41-6P,  
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-43-8P,  
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-50-7P,  
 N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-52-9P,  
 N-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-54-1P,  
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-55-2P,  
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine 786689-57-4P,

N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine 786689-58-5P,  
 N-[3-Chloro-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine 786689-59-6P,  
 5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-62-1P,  
 5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine 786689-63-2P,  
 5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]quinazolin-4-amine 786689-64-3P,  
 5-[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-67-6P,  
 5-[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-68-7P,  
 5-[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine 786689-69-8P,  
 5-[(1R)-2-(Dimethylamino)-1-methylethyl]oxy]-N-[3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]quinazolin-4-amine 786689-70-1P  
 , 5-[2-(Dimethylamino)-2-methylpropoxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine 786689-72-3P,  
 5-[2-(Dimethylamino)ethoxy]-N-[3-methoxy-4-[(5-methylisoxazol-3-yl)methoxy]phenyl]quinazolin-4-amine 786689-75-6P,  
 5-[2-(Dimethylamino)ethoxy]-N-[3-methoxy-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-76-7P,  
 5-[2-(Dimethylamino)ethoxy]-N-[3-fluoro-4-(1,3-thiazol-5-ylmethoxy)phenyl]quinazolin-4-amine 786689-79-0P,  
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine 786689-80-3P,  
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(2S)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-81-4P,  
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-82-5P,  
 5-[2-[Allyl(methyl)amino]ethoxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-83-6P,  
 2-[[2-[[4-[[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino]quinazolin-5-yl]oxy]ethyl](ethyl)amino]ethanol 786689-84-7P,  
 N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1S)-2-[(2-methoxyethyl)(methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine dihydrochloride 786689-85-8P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1R)-2-[ethyl(methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine dihydrochloride 786689-86-9P,  
 5-[(1R)-2-[Allyl(methyl)amino]-1-methylethyl]oxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-87-0P,  
 5-[(1S)-2-[Allyl(methyl)amino]-1-methylethyl]oxy]-N-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine 786689-88-1P,  
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(2S)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-89-2P,  
 N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-5-[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-90-5P,  
 N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(2S)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine 786689-91-6P,  
 N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine hydrochloride 786689-92-7P, N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-amine dihydrochloride 786689-93-8P, 5-[2-(Dimethylamino)-1-methylethoxy]-N-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine 786689-95-0P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-1,1-dimethylethoxy]quinazolin-4-amine 786689-96-1P 786689-97-2P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1S)-


2-[ (2-methoxyethyl) (methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine  
 786689-99-4P, N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1R)-  
 2-[ethyl(methyl)amino]-1-methylethyl]oxy]quinazolin-4-amine  
 786690-00-4P, N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-  
 yl)thio]phenyl]-5-[(2R)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine  
 786690-01-5P, N-[3-Chloro-4-[(1-methyl-1H-imidazol-2-  
 yl)thio]phenyl]-5-[(R)-2-(dimethylamino)-1-methylethyl]oxy]quinazolin-4-  
 amine

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)

(preparation of 4-anilino-quinazoline derivs. as antiproliferative agents)


RN 786688-99-1 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-  
 (dimethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-00-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-  
 (dimethylamino)-1-methylethoxy]- (CA INDEX NAME)




RN 786689-01-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-03-0 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[2-(dimethylamino)propoxy]- (CA INDEX NAME)



RN 786689-04-1 CAPLUS  
CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 786689-06-3 CAPLUS  
CN 4-Quinazolinamine, 5-[2-(dimethylamino)-1-methylethoxy]-N-[4-[(3-fluorophenyl)methoxy]phenyl]- (CA INDEX NAME)




RN 786689-07-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-11-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)




RN 786689-12-1 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-15-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]-5-[2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)



RN 786689-16-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(ethylmethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-17-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(ethylmethylamino)ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1


CRN 786689-16-5

CMF C26 H26 Cl F N4 O2




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 786689-21-2 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)




RN 786689-22-3 CAPLUS

CN Ethanol, 2-[2-[[4-[[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-5-quinazolinyl]oxy]ethyl]methylamino]- (CA INDEX NAME)



RN 786689-23-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(ethylmethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-24-5 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(ethylmethylamino)ethoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 786689-23-4


10 / 554, 202

CMF C25 H26 Cl N5 O2




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 786689-28-9 CAPLUS  
CN Ethanol, 2-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]methylamino]- (CA INDEX NAME)




RN 786689-29-0 CAPLUS

CN Ethanol, 2-[2-[[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]methylamino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 786689-28-9


CMF C25 H26 Cl N5 O3




CM 2

CRN 76-05-1

CMF C2 H F3 O2




RN 786689-30-3 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(dimethylamino)propoxy]- (CA INDEX NAME)



RN 786689-31-4 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[2-(dimethylamino)propoxy]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 786689-30-3  
CMF C26 H26 Cl F N4 O2




CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 786689-33-6 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(dimethylamino)propoxy]- (CA INDEX NAME)




RN 786689-35-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-38-1 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinyloxy)phenyl]-5-[2-(dimethylamino)ethoxy]- (CA INDEX NAME)



RN 786689-39-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-41-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-43-8 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-50-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-52-9 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyrazinylmethoxy)phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-54-1 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-55-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]- (CA INDEX NAME)




RN 786689-57-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(4-thiazolylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]- (CA INDEX NAME)




RN 786689-58-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[5-methyl-3-isoxazolyl]methoxy]phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]- (CA INDEX NAME)




RN 786689-59-6 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)




RN 786689-62-1 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methyl-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)



RN 786689-63-2 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]- (CA INDEX NAME)



RN 786689-64-3 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(2-pyridinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-67-6 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(2-pyrazinylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-68-7 CAPLUS

CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-69-8 CAPLUS


CN 4-Quinazolinamine, 5-[(1R)-2-(dimethylamino)-1-methylethoxy]-N-[3-methyl-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-70-1 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)-2-methylpropoxy]-N-[3-methyl-4-(4-thiazolylmethoxy)phenyl]- (CA INDEX NAME)




RN 786689-72-3 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methoxy-4-[(5-methyl-3-isoxazolyl)methoxy]phenyl]- (CA INDEX NAME)




RN 786689-75-6 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-methoxy-4-(2-pyrazinylmethoxy)phenyl]- (CA INDEX NAME)



RN 786689-76-7 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-[3-fluoro-4-(5-thiazolylmethoxy)phenyl]- (CA INDEX NAME)



RN 786689-79-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1S)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-80-3 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(2S)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-81-4 CAPLUS


CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(2R)-2-(dimethylamino)propoxy]- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-82-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(methyl-2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)



RN 786689-83-6 CAPLUS


CN Ethanol, 2-[2-[[4-[[3-chloro-4-(2-pyridinylmethoxy)phenyl]amino]-5-quinazolinyl]oxy]ethyl]ethylamino]- (CA INDEX NAME)



RN 786689-84-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1S)-2-[(2-methoxyethyl)methylamino]-1-methylethoxy]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 786689-85-8 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-2-(ethylmethylamino)-1-methylethoxy]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 786689-86-9 CAPLUS  
CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-1-methyl-2-(methyl-2-propen-1-ylamino)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-87-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridylmethoxy)phenyl]-5-[(1S)-1-methyl-2-(methyl-2-propenylamino)ethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-88-1 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(2S)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-89-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-5-[(2R)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-90-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(2S)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-91-6 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(2R)-2-(dimethylamino)propoxy]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 786689-92-7 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 786689-93-8 CAPLUS

CN 4-Quinazolinamine, 5-[2-(dimethylamino)-1-methylethoxy]-N-(3-methoxy-4-phenoxyphenyl)- (CA INDEX NAME)




RN 786689-95-0 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[2-(dimethylamino)-1,1-dimethylethoxy]- (CA INDEX NAME)



RN 786689-96-1 CAPLUS


CN 4-Quinazolinamine, 5-[2-(dimethylamino)ethoxy]-N-(3-methoxy-4-phenoxyphenyl)- (CA INDEX NAME)



RN 786689-97-2 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1S)-2-[(2-methoxyethyl)methylamino]-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-99-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-(2-pyridinylmethoxy)phenyl]-5-[(1R)-2-(ethylmethylamino)-1-methylethoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786690-00-4 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(2R)-2-(dimethylamino)propoxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786690-01-5 CAPLUS

CN 4-Quinazolinamine, N-[3-chloro-4-[(1-methyl-1H-imidazol-2-yl)thio]phenyl]-5-[(1R)-2-(dimethylamino)-1-methylethoxy]- (CA INDEX NAME)

Absolute stereochemistry.



IT 786689-36-9P, 2-Chloro-4-[(5-[2-(dimethylamino)ethoxy]quinazolin-4-yl)amino]phenol 786689-40-5P, 2-Chloro-4-[(5-[(1S)-2-(dimethylamino)-1-methylethyl]oxy)quinazolin-4-yl]amino]phenol

786689-45-0P, 2-Chloro-4-[(5-[(1R)-2-(dimethylamino)-1-methylethyl]oxy)quinazolin-4-yl]amino]phenol 786689-48-3P,

4-[(5-[(1R)-2-Amino-1-methylethyl]oxy)quinazolin-4-yl]amino]-2-chlorophenol 786689-56-3P, 2-Chloro-4-[(5-[2-(dimethylamino)-2-

methylpropoxy]quinazolin-4-yl]amino]phenol 786689-60-9P, 4-[(5-[2-(Dimethylamino)ethoxy]quinazolin-4-yl)amino]-2-methylphenol

786689-65-4P, 4-[(5-[(1R)-2-(Dimethylamino)-1-

methylethyl]oxy)quinazolin-4-yl]amino]-2-methylphenol 786689-66-5P, 4-[(5-[(1R)-2-Amino-1-methylethyl]oxy)quinazolin-4-yl]amino]-2-

methylphenol 786689-71-2P, 4-[(5-[2-(Dimethylamino)-2-

methylpropoxy]quinazolin-4-yl]amino]-2-methylphenol 786689-73-4P, 4-[(5-[2-(Dimethylamino)ethoxy]quinazolin-4-yl)amino]-2-methoxyphenol

786689-77-8P, 4-[(5-[2-(Dimethylamino)ethoxy]quinazolin-4-

yl)amino]-2-fluorophenol


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation of 4-anilino-quinazoline derivs. as antiproliferative agents)

RN 786689-36-9 CAPLUS


CN Phenol, 2-chloro-4-[ [5-[2-(dimethylamino)ethoxy]-4-quinazolinyl]amino]-  
(CA INDEX NAME)



RN 786689-40-5 CAPLUS

CN Phenol, 2-chloro-4-[ [5-[(1S)-2-(dimethylamino)-1-methylethoxy]-4-  
quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-45-0 CAPLUS

CN Phenol, 2-chloro-4-[ [5-[(1R)-2-(dimethylamino)-1-methylethoxy]-4-  
quinazolinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-48-3 CAPLUS


CN Phenol, 4-[5-[(1R)-2-(dimethylamino)-1-methylethoxy]-4-quinazolinyl]amino]-2-chloro-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 786689-56-3 CAPLUS

CN Phenol, 2-chloro-4-[5-[(2-dimethylamino)-2-methylpropoxy]-4-quinazolinyl]amino]- (CA INDEX NAME)



RN 786689-60-9 CAPLUS


CN Phenol, 4-[5-[(2-dimethylamino)ethoxy]-4-quinazolinyl]amino]-2-methyl-  
(CA INDEX NAME)



RN 786689-65-4 CAPLUS

CN Phenol, 4-[[5-[(1R)-2-(dimethylamino)-1-methylethoxy]-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 786689-66-5 CAPLUS


CN Phenol, 4-[[5-[(1R)-2-amino-1-methylethoxy]-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 786689-71-2 CAPLUS

CN Phenol, 4-[ [5-[2-(dimethylamino)-2-methylpropoxy]-4-quinazolinyl]amino]-2-methyl- (CA INDEX NAME)




RN 786689-73-4 CAPLUS

CN Phenol, 4-[ [5-[2-(dimethylamino)ethoxy]-4-quinazolinyl]amino]-2-methoxy- (CA INDEX NAME)



RN 786689-77-8 CAPLUS

CN Phenol, 4-[ [5-[2-(dimethylamino)ethoxy]-4-quinazolinyl]amino]-2-fluoro- (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

10/ 554,202

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:10:44 ON 02 SEP 2008)

FILE 'REGISTRY' ENTERED AT 14:11:00 ON 02 SEP 2008

L1                   STRUCTURE UPLOADED  
L2                   411 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:11:37 ON 02 SEP 2008

L3                   9 S L2

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	49.53	228.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.20	-7.20

STN INTERNATIONAL LOGOFF AT 14:12:17 ON 02 SEP 2008